Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Лечение артериальной гипертензии у пациентов с избыточной массой тела - Журнал Системные Гипертензии Том 12, №3
Лечение артериальной гипертензии у пациентов с избыточной массой тела
Кукес В.Г, Аникин Г.С., Андреевская Е.М., Ашуркова Е.А. Лечение артериальной гипертензии у пациентов с избыточной массой тела. Системные гипертензии. 2015; 12 (3): 46–49.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
При лечении артериальной гипертензии у пациентов с избыточной массой тела целью является не только нормализация артериального давления, но и улучшение показателей эндотелиальной функции, снижение инсулинорезистентности, нормализация показателей липидного обмена. Одни из препаратов, обладающие широкими терапевтическими возможностями и большой доказательной базой, – агонисты I1-имидазолиновых рецепторов, которые могут назначаться как в монотерапии, так и в составе комбинированной терапии лицам с избыточной массой тела.
Ключевые слова: артериальная гипертензия, избыточная масса тела, моксонидин, Физиотенз.
Key words: arterial hypertension, overweight, moxonidine, Physiotens.
Ключевые слова: артериальная гипертензия, избыточная масса тела, моксонидин, Физиотенз.
________________________________________________
Key words: arterial hypertension, overweight, moxonidine, Physiotens.
Полный текст
Список литературы
1. Kotseva K et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015.
2. Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299–306.
3. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
4. Красильникова Е.И., Баранова Е.И., Благосклонная Я.В. и др. Терапия артериальной гипертензии у больных с метаболическим синдромом. Справ. поликлин. врача. 2011; 9: 23–7. / Krasil'nikova E.I., Baranova E.I., Blagosklonnaia Ia.V. i dr. Terapiia arterial'noi gipertenzii u bol'nykh s metabolicheskim sindromom. Sprav. poliklin. vracha. 2011; 9: 23–7. [in Russian]
5. Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653–61.
6. Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022–9.
7. Van Sloten TT Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299–305.
8. Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343–8.
9. Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315–22.
10. Theodor R, Weimann HJ, Weber W et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153–9.
11. Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967–72.
12. Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245–53.
13. Krespi PG Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463–7.
14. Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479–82.
15. Schwarz W, Kandziora J. Long-term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616–20.
16. Prichard BNC, Küster LJ, Hughes PR et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo – and active – comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51.
17. Sanjuliani AE, Genelhu de Abreu V, Ueleres Braga J, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19–25.
18. Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.
19. Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684–7.
20. Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541–5.
2. Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299–306.
3. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
4. Krasil'nikova E.I., Baranova E.I., Blagosklonnaia Ia.V. i dr. Terapiia arterial'noi gipertenzii u bol'nykh s metabolicheskim sindromom. Sprav. poliklin. vracha. 2011; 9: 23–7. [in Russian]
5. Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653–61.
6. Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022–9.
7. Van Sloten TT Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299–305.
8. Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343–8.
9. Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315–22.
10. Theodor R, Weimann HJ, Weber W et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153–9.
11. Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967–72.
12. Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245–53.
13. Krespi PG Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463–7.
14. Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479–82.
15. Schwarz W, Kandziora J. Long-term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616–20.
16. Prichard BNC, Küster LJ, Hughes PR et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo – and active – comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51.
17. Sanjuliani AE, Genelhu de Abreu V, Ueleres Braga J, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19–25.
18. Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.
19. Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684–7.
20. Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541–5.
2. Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299–306.
3. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
4. Красильникова Е.И., Баранова Е.И., Благосклонная Я.В. и др. Терапия артериальной гипертензии у больных с метаболическим синдромом. Справ. поликлин. врача. 2011; 9: 23–7. / Krasil'nikova E.I., Baranova E.I., Blagosklonnaia Ia.V. i dr. Terapiia arterial'noi gipertenzii u bol'nykh s metabolicheskim sindromom. Sprav. poliklin. vracha. 2011; 9: 23–7. [in Russian]
5. Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653–61.
6. Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022–9.
7. Van Sloten TT Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299–305.
8. Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343–8.
9. Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315–22.
10. Theodor R, Weimann HJ, Weber W et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153–9.
11. Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967–72.
12. Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245–53.
13. Krespi PG Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463–7.
14. Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479–82.
15. Schwarz W, Kandziora J. Long-term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616–20.
16. Prichard BNC, Küster LJ, Hughes PR et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo – and active – comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51.
17. Sanjuliani AE, Genelhu de Abreu V, Ueleres Braga J, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19–25.
18. Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.
19. Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684–7.
20. Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541–5.
________________________________________________
2. Åkesson A et al. Low-Risk Diet and Lifestyle Habits in the Primary Prevention of Myocardial Infarction in MenA Population-Based Prospective Cohort Study J Am Coll Cardiol 2014; 64 (13): 1299–306.
3. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 10: 4–12. [in Russian]
4. Krasil'nikova E.I., Baranova E.I., Blagosklonnaia Ia.V. i dr. Terapiia arterial'noi gipertenzii u bol'nykh s metabolicheskim sindromom. Sprav. poliklin. vracha. 2011; 9: 23–7. [in Russian]
5. Bruyndonckx L et al. Diet, exercise, and endothelial function in obese adolescents. Pediatrics 2015; 135 (3): e653–61.
6. Walther G. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol 2015; 35 (4): 1022–9.
7. Van Sloten TT Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension 2014; 64 (6): 1299–305.
8. Topal E et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006; 6 (5): 343–8.
9. Jacob S et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112 (6): 315–22.
10. Theodor R, Weimann HJ, Weber W et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16 (2): 153–9.
11. Mitrovic V, Patyna W, Hütting J et al. Hemodinamic and neurohumoral effect of moxonidine in patients with essential hypertension. Cardiovase Drugs Ther 1991; 5: 967–72.
12. Kirch W, Hutt HJ, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245–53.
13. Krespi PG Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463–7.
14. Schachter M, Mitchell G, Nizol C et al. Antihipertensive efficacy of moxonidine in primary care: a «REAL-LIFE» study. Int J Clin Pract 2003; 57 (6): 479–82.
15. Schwarz W, Kandziora J. Long-term experiences with moxonidine, a new antihypertensive. Fortsch Med 1990; 32: 616–20.
16. Prichard BNC, Küster LJ, Hughes PR et al. Dose relation of blood pressure reduction with moxonidine findings from three placebo – and active – comntrolled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51.
17. Sanjuliani AE, Genelhu de Abreu V, Ueleres Braga J, Francischetti EA. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin and metabolic profile in obese hypertensive patients. J Clin Basic Cardial 2004; 7: 19–25.
18. Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens 2013; 2013: 541689.
19. Deftereos S et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013; 112 (5): 684–7.
20. Krupicka J et al. The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial). [Article in Czech] Vnitr Lek 2011; 57 (6): 541–5.
Авторы
В.Г.Кукес1, Г.С.Аникин*1,2, Е.М.Андреевская2, Е.А.Ашуркова2
1 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБУ Поликлиника №3 Управления делами Президента РФ. 29090, Россия, Москва, Грохольский пер., д. 31
*medi321@mail.ru
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 Out-Patient Сlinic №3 of Administration of the President of Russian Federation. 129090, Russian Federation, Moscow, Grokhol'skii per., d. 31
*medi321@mail.ru
1 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБУ Поликлиника №3 Управления делами Президента РФ. 29090, Россия, Москва, Грохольский пер., д. 31
*medi321@mail.ru
________________________________________________
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 Out-Patient Сlinic №3 of Administration of the President of Russian Federation. 129090, Russian Federation, Moscow, Grokhol'skii per., d. 31
*medi321@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.